DNAY News and Press, Codex DNA Inc. From 01/10/22

Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technology Pfizer’s successful development and commercialization of licensed products could result in milestone pay...

Wednesday will go down in history for Codex DNA (NASDAQ: DNAY) . The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed pharmaceutical giant. Codex DNA disclosed in a regulatory filing that it has ente...

Codex DNA (NASDAQ:DNAY) is trading ~8.1% higher in the pre-market after the company announced an agreement with Pfizer (NYSE:PFE) to jointly advance its synthetic DNA platform BioXP. Under the Research Collaboration and License Agreement, the duo will collaborate to enhance the BioX...

SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic genome of the SARS-CoV-2 virus for the highly mutated and contagious Omicron variant (B.1.1.529 ...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Proven CleanCap® reagent technology from TriLink BioTechnologies delivers significant time and cost savings for mRNA-based vaccine and therapeutic applications Codex DNA scientists to share latest data and showcase mRNA synthesis solutions at upcoming mRNA conference ...

The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Like the internet revolution, companies that enable or effectively harness synthetic...

Codex DNA, Inc. (DNAY) Q3 2021 Earnings Conference Call November 09, 2021, 05:00 AM ET Company Participants Richard Lepke - Director of IR Todd Nelson - CEO Jennifer McNealey - CFO Dan Gibson - Chief Technology Officer Conference Call Participants Brandon Couillard - Jefferies Presentation Op...

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present virtually at the 12th Annual Jefferies London Hea...

Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q3 2021 Earnings Call Nov 09, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q3 2021 Earnings Call Transcript